166 related articles for article (PubMed ID: 38160354)
1. Odor Identification Across Time in Mutation Carriers and Non-Carriers in Autosomal-Dominant Alzheimer's Disease.
Almkvist O; Larsson M; Graff C
J Alzheimers Dis; 2024; 97(2):587-598. PubMed ID: 38160354
[TBL] [Abstract][Full Text] [Related]
2. The
Almkvist O; Graff C
Genes (Basel); 2021 Dec; 12(12):. PubMed ID: 34946903
[TBL] [Abstract][Full Text] [Related]
3. APOE ε4 influences cognitive decline positively in APP and negatively in PSEN1 mutation carriers with autosomal-dominant Alzheimer's disease.
Almkvist O; Johansson C; Laffita-Mesa J; Thordardottir S; Graff C
Eur J Neurol; 2022 Dec; 29(12):3580-3589. PubMed ID: 36039401
[TBL] [Abstract][Full Text] [Related]
4. Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimer's Disease.
Almkvist O; Rodriguez-Vieitez E; Thordardottir S; Amberla K; Axelman K; Basun H; Kinhult-Ståhlbom A; Lilius L; Remes A; Wahlund LO; Viitanen M; Lannfelt L; Graff C
J Int Neuropsychol Soc; 2017 Mar; 23(3):195-203. PubMed ID: 28079014
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal cognitive decline in autosomal-dominant Alzheimer's disease varies with mutations in APP and PSEN1 genes.
Almkvist O; Rodriguez-Vieitez E; Thordardottir S; Nordberg A; Viitanen M; Lannfelt L; Graff C
Neurobiol Aging; 2019 Oct; 82():40-47. PubMed ID: 31386938
[TBL] [Abstract][Full Text] [Related]
6. A Three-Factor Structure of Cognitive Functioning Among Unimpaired Carriers and Non-Carriers of Autosomal-Dominant Alzheimer's Disease.
Guzmán-Vélez E; Jaimes S; Aguirre-Acevedo DC; Norton DJ; Papp KV; Amariglio R; Rentz D; Baena A; Henao E; Tirado V; Muñoz C; Giraldo M; Sperling RA; Lopera F; Quiroz YT
J Alzheimers Dis; 2018; 65(1):107-115. PubMed ID: 30040714
[TBL] [Abstract][Full Text] [Related]
7. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
[TBL] [Abstract][Full Text] [Related]
8. A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer's disease.
Almkvist O; Nordberg A
Alzheimers Res Ther; 2023 May; 15(1):89. PubMed ID: 37131241
[TBL] [Abstract][Full Text] [Related]
9. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.
Twohig D; Rodriguez-Vieitez E; Sando SB; Berge G; Lauridsen C; Møller I; Grøntvedt GR; Bråthen G; Patra K; Bu G; Benzinger TLS; Karch CM; Fagan A; Morris JC; Bateman RJ; Nordberg A; White LR; Nielsen HM;
Acta Neuropathol Commun; 2018 Nov; 6(1):130. PubMed ID: 30477568
[TBL] [Abstract][Full Text] [Related]
10. PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers.
Ghisays V; Lopera F; Goradia DD; Protas HD; Malek-Ahmadi MH; Chen Y; Devadas V; Luo J; Lee W; Baena A; Bocanegra Y; Guzmán-Vélez E; Pardilla-Delgado E; Vila-Castelar C; Fox-Fuller JT; Hu N; Clayton D; Thomas RG; Alvarez S; Espinosa A; Acosta-Baena N; Giraldo MM; Rios-Romenets S; Langbaum JB; Chen K; Su Y; Tariot PN; Quiroz YT; Reiman EM;
Neuroimage Clin; 2021; 31():102749. PubMed ID: 34252876
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study.
Day GS; Musiek ES; Roe CM; Norton J; Goate AM; Cruchaga C; Cairns NJ; Morris JC
JAMA Neurol; 2016 Sep; 73(9):1125-32. PubMed ID: 27454811
[TBL] [Abstract][Full Text] [Related]
12. Examining Sex Differences in Markers of Cognition and Neurodegeneration in Autosomal Dominant Alzheimer's Disease: Preliminary Findings from the Colombian Alzheimer's Prevention Initiative Biomarker Study.
Vila-Castelar C; Guzmán-Vélez E; Pardilla-Delgado E; Buckley RF; Bocanegra Y; Baena A; Fox-Fuller JT; Tirado V; Muñoz C; Giraldo M; Acosta-Baena N; Rios-Romenets S; Langbaum JB; Tariot PN; Lopera F; Reiman EM; Quiroz YT
J Alzheimers Dis; 2020; 77(4):1743-1753. PubMed ID: 32925067
[TBL] [Abstract][Full Text] [Related]
13. White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer's disease that emerge prior to dementia.
Schoemaker D; Zanon Zotin MC; Chen K; Igwe KC; Vila-Castelar C; Martinez J; Baena A; Fox-Fuller JT; Lopera F; Reiman EM; Brickman AM; Quiroz YT
Alzheimers Res Ther; 2022 Jun; 14(1):89. PubMed ID: 35768838
[TBL] [Abstract][Full Text] [Related]
14. The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.
Ayutyanont N; Langbaum JB; Hendrix SB; Chen K; Fleisher AS; Friesenhahn M; Ward M; Aguirre C; Acosta-Baena N; Madrigal L; Muñoz C; Tirado V; Moreno S; Tariot PN; Lopera F; Reiman EM
J Clin Psychiatry; 2014 Jun; 75(6):652-60. PubMed ID: 24816373
[TBL] [Abstract][Full Text] [Related]
15. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series.
Ryan NS; Nicholas JM; Weston PSJ; Liang Y; Lashley T; Guerreiro R; Adamson G; Kenny J; Beck J; Chavez-Gutierrez L; de Strooper B; Revesz T; Holton J; Mead S; Rossor MN; Fox NC
Lancet Neurol; 2016 Dec; 15(13):1326-1335. PubMed ID: 27777022
[TBL] [Abstract][Full Text] [Related]
16. Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study.
Chatterjee P; Lim WL; Shui G; Gupta VB; James I; Fagan AM; Xiong C; Sohrabi HR; Taddei K; Brown BM; Benzinger T; Masters C; Snowden SG; Wenk MR; Bateman RJ; Morris JC; Martins RN
J Alzheimers Dis; 2016; 50(3):887-94. PubMed ID: 26836186
[TBL] [Abstract][Full Text] [Related]
17. Functional Connectivity of Default Mode Network Subsystems in the Presymptomatic Stage of Autosomal Dominant Alzheimer's Disease.
Zhao T; Quan M; Jia J
J Alzheimers Dis; 2020; 73(4):1435-1444. PubMed ID: 31929167
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the NIH Toolbox Odor Identification Test across normal cognition, amnestic mild cognitive impairment, and dementia due to Alzheimer's disease.
Echevarria-Cooper SL; Ho EH; Gershon RC; Weintraub S; Kahnt T
Alzheimers Dement; 2024 Jan; 20(1):288-300. PubMed ID: 37603693
[TBL] [Abstract][Full Text] [Related]
19. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.
Reijs BLR; Ramakers IHGB; Elias-Sonnenschein L; Teunissen CE; Koel-Simmelink M; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Johannsen P; Vanderstichele H; Verhey F; Devanand DP; Visser PJ
J Alzheimers Dis; 2017; 60(3):1025-1034. PubMed ID: 28984603
[TBL] [Abstract][Full Text] [Related]
20. Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's disease.
Schultz SA; Shirzadi Z; Schultz AP; Liu L; Fitzpatrick CD; McDade E; Barthelemy NR; Renton A; Esposito B; Joseph-Mathurin N; Cruchaga C; Chen CD; Goate A; Allegri RF; Benzinger TLS; Berman S; Chui HC; Fagan AM; Farlow MR; Fox NC; Gordon BA; Day GS; Graff-Radford NR; Hassenstab JJ; Hanseeuw BJ; Hofmann A; Jack CR; Jucker M; Karch CM; Koeppe RA; Lee JH; Levey AI; Levin J; Martins RN; Mori H; Morris JC; Noble J; Perrin RJ; Rosa-Neto P; Salloway SP; Sanchez-Valle R; Schofield PR; Xiong C; Johnson KA; Bateman RJ; Sperling RA; Chhatwal JP;
Aging Cell; 2023 Aug; 22(8):e13871. PubMed ID: 37291760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
